Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy ...
Acquisition builds on UCB’s 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies.Lead investigational asset, NRTX-1001, a ...
The takeover – which, if completed, will be the third acquisition for UCB this decade – involves an upfront payment of $650 ...
The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy ...
Frontotemporal dementia is a brain disease that affects the parts of your brain responsible for behavior, speech and memory. “Frontotemporal” stems from the names frontal and temporal lobes, which are ...
The human language system appears to recruit a broad network of frontal and temporal brain regions. Even though different aspects of language processing have by now been confidently apportioned to ...
Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results